Business Context and Reporting Period
Company: Accuray Incorporated
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 29, 2008 (Fiscal Q3 2008)
Business Overview: Accuray designs, develops, and sells the CyberKnife system, an image-guided robotic radiosurgery system used to treat solid tumors. The company operates in a single segment and sells directly and through distributors in over 50 countries. As of March 31, 2008, 134 CyberKnife systems were installed globally.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2008 | Nine Months Ended Mar 31, 2008 | Three Months Ended Mar 31, 2007 | Nine Months Ended Mar 31, 2007 |
|---|---|---|---|---|
| Total Net Revenue | $58,758 | $159,442 | $37,340 | $96,458 |
| Gross Profit | $26,283 | $80,056 | $21,118 | $55,123 |
| Gross Margin % | 44.7% | 50.2% | 56.6% | 57.1% |
| Operating Loss | $(1,084) | $(354) | $(1,763) | $(8,121) |
| Net Income (Loss) | $584 | $5,192 | $(785) | $(6,118) |
| Diluted EPS | $0.01 | $0.09 | $(0.02) | $(0.26) |
| Cash & Equivalents (End of Period) | $63,047 | Balance Sheet Data | ||
| Short-term Investments | $78,491 | Balance Sheet Data | ||
| Long-term Investments | $23,963 | Balance Sheet Data | ||
| Total Assets | $293,862 | Balance Sheet Data | ||
| Total Liabilities | $166,994 | Balance Sheet Data | ||
| Stockholders' Equity | $126,868 | Balance Sheet Data |
Liquidity: Net cash used in operating activities was $18.0 million for the nine months ended March 31, 2008. The company held $165.5 million in cash, cash equivalents, and investments as of March 31, 2008.
Material Changes vs. Prior Period
- Revenue Growth: Total net revenue increased 57% year-over-year for the quarter ($58.8M vs. $37.3M) and 65% for the nine-month period ($159.4M vs. $96.5M). Growth was driven by product sales (including conversions from shared ownership programs) and increased service revenue.
- Profitability: The company reported a net income of $584,000 for the quarter and $5.2 million for the nine months, compared to net losses of $785,000 and $6.1 million in the prior year periods. This turnaround was aided by higher revenue and interest income, partially offset by increased operating expenses.
- Gross Margin Compression: Gross margin decreased to 44.7% in the quarter (from 56.6% prior year) and 50.2% for the nine months (from 57.1% prior year). Management attributed this to the sale of CyberKnife systems previously held in shared ownership programs and increased upgrade services in Japan, which carry lower margins than conventional unit sales.
- Operating Expenses: Selling, marketing, R&D, and G&A expenses increased in absolute terms due to headcount growth and stock-based compensation, but decreased as a percentage of revenue due to revenue leverage.
- Investment Portfolio: The company invested excess cash into short-term and long-term investments ($102.5M total). Notably, $21.3 million in Auction Rate Securities (ARS) were reclassified to long-term investments due to failed auctions and liquidity concerns.
Guidance, Outlook, Risks, and Unusual Items
- Backlog: As of March 31, 2008, total backlog was approximately $601.7 million, consisting of $332.1 million in system sales and $269.6 million in service plans. Of this, $216.1 million is contingent on regulatory approvals or financing.
- Shared Ownership Programs: Revenue from shared ownership programs is expected to decline in subsequent quarters following the sale of several systems previously held under these programs.
- Internal Controls: The company disclosed material weaknesses in internal controls over financial reporting identified in the prior year audit, relating to segregation of duties and revenue recognition. Management is implementing remediation but concluded disclosure controls were not effective as of March 31, 2008.
- Investment Risk (ARS): The company holds $21.3 million in Auction Rate Securities which are currently illiquid due to failed auctions. A temporary impairment of $1.1 million was recorded in other comprehensive income. The company has modified its investment policy to preclude further ARS exposure.
- Regulatory & Market Risks: Risks include potential delays in Certificate of Need (CON) approvals, changes in Medicare reimbursement rates, and reliance on single-source suppliers for critical components.
Investor Verification Checklist
- Revenue Recognition: Verify the timing of revenue recognition for legacy service plans and the impact of shared ownership conversions on gross margins.
- Liquidity of Investments: Assess the risk associated with the $21.3 million in illiquid Auction Rate Securities and the potential for future impairment charges.
- Internal Controls: Monitor progress on remediation of material weaknesses in internal controls over financial reporting.
- Backlog Conversion: Track the conversion rate of the $216.1 million contingent backlog into recognized revenue, given regulatory and financing dependencies.
- Reimbursement Rates: Review updates on Medicare and third-party payer reimbursement rates for CyberKnife procedures, as these directly impact customer purchasing decisions.